News from Zyme and the companies we work with.

June 20, 17

LifeArc, previously MRC Technology, set to transform the medical research landscape

Investment will focus on new innovations in therapeutics for neurodegeneration, antibiotic resistance, cancer and respiratory diseases Newly rebranded UK medical research charity has also established two new funds to progress medical science 15 June 2017:  LifeArc, the UK medical research … Continue reading

June 15, 17

Horizon Discovery’s RNA reference standards endorsed by Thermo Fisher Scientific’s White Paper for use in cancer research testing

Cambridge, UK, 15 June 2017: Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), the world leader in the application of gene editing technologies, today notes its complete RNA reference standards product range have been endorsed by Thermo Fisher … Continue reading

June 14, 17

Mologic Receives CE Mark Approval for PERiPLEX Diagnostic for Infection in Patients on Peritoneal Dialysis

Newly launched point-of-care test detects biomarkers of infection using lateral flow immunoassay Provides results in less than 10 minutes, enabling rapid diagnosis of infection and prevention of damage to the peritoneal membrane Bedfordshire, UK, June 14th, 2017:   Mologic Ltd, a diagnostics … Continue reading

June 14, 17

Horizon Discovery Announces Progress of its Gene and Cell Therapy Platform for Contract Service and Therapeutic Applications

Platform comprises Horizon’s viral, nuclease and transposon gene editing technologies for research and development Three new contract wins contributing a value of more than $2 million in 2017 with potential for long-term alliance development Cambridge, UK, 14 June 2017: Horizon … Continue reading

June 13, 17

Irvine Scientific Expands in Southern California – Adds New Center of Excellence for Research and Development

The Company adds a fifth building in California to expand R&D capabilities  SANTA ANA, California – June 13, 2017:  Irvine Scientific, a world leader in the development and manufacture of cell culture media, today announced the expansion of its Orange … Continue reading

June 13, 17

TTP plc and Innova Biosciences extend partnership to develop rapid point-of-care diagnostics

Innova to continue to provide custom bioconjugation services to support TTP’s Desktop Biology initiative Cambridge, UK, 13 June 2017:  TTP plc,  Europe’s leading technology and product development company, today announces its ongoing partnership with Innova Biosciences (Innova), a specialist provider of … Continue reading

June 12, 17

License Agreement Signed for Manufacture and Supply of Novel Limb Sterilisation Device

Health Enterprise East facilitates deal between Derby Hospitals NHS Foundation Trust and Pentland Medical  Cambridge, UK, 12 June 2017 – Health Enterprise East (HEE), a leading NHS innovation hub, today announced the signing of a manufacture and distribution agreement for a … Continue reading

June 6, 17

NemaMetrix Introduces Fluorescent Staining Kits for Improved Phenotyping in model organism C. elegans

Fluorescent kits designed for use with ScreenChip System for automatic screening and phenotyping Oregon, USA, 6th June 2017: NemaMetrix, a company developing nematode-based drug development and screening technologies, today announced the launch of its first series of RediStain™ fluorescent kits for … Continue reading

June 1, 17

ATUM and Horizon Discovery Announce Collaboration and Technology Cross-License to Simplify and Speed Bioproduction Cell Line Development

Horizon’s CHO SOURCE Platform now incorporates exclusive ATUM vectors as standard ATUM has licensed Horizon’s CHO SOURCE platform to offer cell line development services with its Leap-In Transposase Technology Newark, CA, and Cambridge, UK, June 1, 2017: ATUM (formerly DNA2.0, … Continue reading

May 30, 17

Horizon Discovery Group plc Announces Preliminary Results for the Year Ended 31 December 2016

Revenue of £24.1m in line with guidance Revenue growth of 19% driven by outperformance in Products business Gross margin improvement to 54% driven by increased Product sales volumes Operational efficiencies taking effect as the Group progresses its Path to Profit … Continue reading